Cognition Therapeutics’ CT1812 improves dementia with Lewy bodies outcomes, reducing anxiety, hallucinations, and functional decline in trials.
Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?
Where Today's News Shapes Tomorrow
